

CITATION REPORT

List of articles citing

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

DOI: 10.1182/blood.v89.9.3323
Blood, 1997, 89, 3323-3329.

Source: <https://exaly.com/paper-pdf/28407141/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
749	Aging and cancer: issues of basic and clinical science. 1997 , 89, 1489-97		113
748	Acute leukemia. 1997 , 11, 657		
747	Therapeutic Options in the Management of Acute Myelogenous Leukemia in Adults. 1997 , 4, 399-406		1
746	Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy. <i>Blood</i> , 1997 , 90, 2863-2892	2.2	344
745	Geriatric clinical pharmacologist and medical oncologist: a new partnership?. 1997 , 62, 361-4		1
744	Clonality studies in acute myeloid leukemia. 1998 , 12, 117-20		15
743	Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. 1998 , 12, 1367-74		26
742	Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative Group. 1998 , 12, 1522-6		7
741	Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. 1998 , 103, 1083-91		59
740	Acute myeloid leukemia in the elderly. 1998 , 12, 145-53		29
739	Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. 1998 , 339, 1649-56		506
738	Cancer chemotherapy in the elderly. 1998 , 28, 463-73		38
737	Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with ⁹⁹ Tc(m)-MIBI. 1998 , 77, 1732-6		8
736	The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. 1998 , 18, 3604-11		160
735	Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. 1998 , 31, 521-31		59
734	Intensifying induction therapy in acute myeloid leukemia by an infusional chemotherapy schedule. 1998 , 16, 542-3		
733	Pathogenetic Aspects of Myelodysplastic Syndromes. 1998 , 3, 119-42		

732	Hypomethylation Status of CpG Sites at the Promoter Region and Overexpression of the Human MDR1 Gene in Acute Myeloid Leukemias. <i>Blood</i> , 1998 , 92, 4296-4307	2.2	157
731	A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031). <i>Blood</i> , 1998 , 91, 3607-3615	2.2	259
730	Pgp and MRP Activities Using Calcein-AM Are Prognostic Factors in Adult Acute Myeloid Leukemia Patients. <i>Blood</i> , 1998 , 91, 4480-4488	2.2	159
729	Characterization and Use of an Antibody Detecting the CBF β SMMHC Fusion Protein in inv(16)/t(16;16)-Associated Acute Myeloid Leukemias. <i>Blood</i> , 1998 , 91, 1882-1890	2.2	19
728	Biological Features of Acute Myeloid Leukemia in the Elderly. <i>Blood</i> , 1998 , 92, 697-699	2.2	8
727	Management of acute myeloid leukemia in elderly patients. 1999 , 17, 3569-76		197
726	Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. 1999 , 17, 2831-9		81
725	Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar). <i>Blood</i> , 1999 , 93, 787-795	2.2	140
724	Microsatellite Instability and p53 Mutations Are Associated With Abnormal Expression of the MSH2 Gene in Adult Acute Leukemia. <i>Blood</i> , 1999 , 94, 733-740	2.2	104
723	Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid Leukemia. <i>Blood</i> , 1999 , 94, 1046-1056	2.2	153
722	De novo and secondary acute myeloid leukemia in patients over the age of 65: a review of fifty-six successive and unselected cases from a general hospital. 1999 , 35, 289-96		13
721	Modulation of multidrug resistance (MDR) in hematological malignancies. 1999 , 10, S53-S60		19
720	Molecular therapeutics of myelodysplasia and myelodysplasia-related leukaemias. 1999 , 3, 151-163		
719	Idarubicin including regimens in acute myelogenous leukemia in elderly patients. 1999 , 32, 59-68		6
718	Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia. 1999 , 104, 307-12		24
717	P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. 1999 , 105, 676-83		51
716	Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. 1999 , 106, 92-9		42
715	High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone. 1999 , 106, 627-33		22

714	Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?. 1999 , 13, 258-65	33
713	Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells. 1999 , 13, 910-7	29
712	Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. 1999 , 13, 843-9	49
711	Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. 1999 , 13, 1943-53	65
710	Acute myeloid leukemia. 1999 , 341, 1051-62	1160
709	Acute myeloid leukemia in the elderly: <i>per aspera ad astra</i> 1999 , 23, 603-13	17
708	Underrepresentation of patients 65 years of age or older in cancer-treatment trials. 1999 , 341, 2061-7	1738
707	Current Clinical Practice: Application of Resistance Reversal Agents in Hematologic Malignancies. 2000 , 5, 343-58	1
706	Chemotherapy in the elderly: pharmacologic considerations. 2000 , 7, 548-56	58
705	Repetitive analyses of P-glycoprotein in chronic myeloid leukaemia. 2000 , 55, 215-21	3
704	Multidrug resistance transporters and modulation. 2000 , 12, 450-8	305
703	Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. 2000 , 28, 318-28	47
702	P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. 2000 , 108, 703-9	37
701	Can multidrug resistance mechanisms be modified?. 2000 , 110, 285-91	20
700	Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein. 2000 , 110, 370-8	15
699	Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. 2000 , 110, 591-8	18
698	Aggressive lymphoma in the elderly. 2000 , 33, 119-28	7
697	Treatment of acute myelogenous leukemia in older adults. 2000 , 14, 480-7	59

696	Drug resistance factors in acute myeloid leukemia: a comparative analysis. 2000 , 14, 68-76		46
695	Novel mechanisms of drug resistance in leukemia. 2000 , 14, 467-73		160
694	Microsatellite instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature. 2000 , 14, 1044-51		36
693	Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. 2000 , 14, 636-41		45
692	Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia. 2000 , 14, 712-5		10
691	Survival time in a population-based consecutive series of adult acute myeloid leukemia--the prognostic impact of karyotype during the time period 1976-1993. 2000 , 14, 1039-43		13
690	P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. 2000 , 14, 1018-24		32
689	Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. 2000 , 111, 334-337		
688	Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia. 2000 , 111, 565-569		1
687	Competitive reverse transcription-polymerase chain reaction assay for quantification of human multidrug resistance 1 (MDR1) gene expression in fresh leukemic cells. 2000 , 135, 199-209		8
686	A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. 2000 , 24, 567-74		56
685	MEIS1 and HOXA7 genes in human acute myeloid leukemia. 2000 , 24, 849-55		58
684	Development of multidrug-resistance convertors: sense or nonsense?. <i>Investigational New Drugs</i> , 2000 , 18, 205-20	4.3	69
683	P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. <i>Blood</i> , 2000 , 95, 2897-2904	2.2	125
682	The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. <i>Blood</i> , 2000 , 96, 870-877	2.2	108
681	Erratum in Ledru et al. Alteration of tumor necrosis factor- β -cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. <i>Blood</i> . 2000;95:3191-3198.. <i>Blood</i> , 2000 , 96, 1673-1673	2.2	
680	How I treat older patients with AML. <i>Blood</i> , 2000 , 96, 1670-1673	2.2	101
679	Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. 2000 , 18, 1867-75		41

678	P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. 2000 , 18, 1837-44	72
677	Therapy-Related Acute Leukemia. 2000 , 20, 71-81	35
676	The Acute Erythroleukemias. 2000 , 20, 119-137	19
675	Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. 2000 , 18, 3447-52	56
674	Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein. 2000 , 36, 428-34	53
673	Leukemia relapse reconsidered from the molecular aspect. 2000 , 37, 527-34	1
672	Acute myeloid leukemia in the elderly: results of an individualized approach in two centres. 2000 , 39, 521-30	5
671	In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. 2000 , 11, 564-8	21
670	Acute myelogenous leukemia and aging. Clinical interactions. 2000 , 14, 251-67	55
669	Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line. 2000 , 39, 194-204	47
668	Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines. 2001 , 42, 721-9	2
667	Prognostic factors in acute myeloid leukaemia. 2001 , 14, 65-75	40
666	Biology and therapy of secondary leukaemias. 2001 , 14, 119-37	32
665	Acute myeloid leukaemia (AML): treatment of the older patient. 2001 , 14, 139-51	15
664	Chemotherapy resistance in acute myeloid leukaemia. 2001 , 14, 211-33	29
663	The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. 2001 , 14, 497-529	112
662	Significance of MDR1, MRP1, GSTpi and GSTmu mRNA expression in acute lymphoblastic leukemia in Indian patients. 2001 , 167, 73-83	7
661	A practical approach to the older patient with cancer. 2001 , 25, 7-76	8

660	Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group. 2001 , 42, 57-65		9
659	First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia. 2001 , 40, 305-13		19
658	Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia. 2001 , 40, 335-43		23
657	Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies. 2001 , 41, 493-500		5
656	MDR-1 expression and deletions of chromosomes 7 and 5(Q) separately indicate adverse prognosis in AML. 2001 , 40, 613-23		6
655	Interactions between P-glycoprotein and drugs used in the supportive care of acute myeloid leukemia patients. 2001 , 42, 177-85		3
654	Therapy of acute myeloid leukemia. 2001 , 8, 62-78		21
653	Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. 2001 , 19, 3244-54		733
652	Drug resistance mechanisms in acute leukemia. 2001 , 13, 21-6		36
651	Mylotarg: antibody-targeted chemotherapy comes of age. 2001 , 13, 522-7		94
650	Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. <i>Blood</i> , 2001 , 98, 988-94	2.2	176
649	The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. <i>Blood</i> , 2001 , 98, 1312-20	2.2	742
648	MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2001 , 97, 3605-11	2.2	71
647	JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. <i>Blood</i> , 2001 , 97, 502-8	2.2	68
646	Methylation profiling in acute myeloid leukemia. <i>Blood</i> , 2001 , 97, 2823-9	2.2	274
645	Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. <i>Blood</i> , 2001 , 98, 3212-20	2.2	352
644	Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. <i>Blood</i> , 2001 , 98, 3541-53	2.2	110
643	Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status. <i>Blood</i> , 2001 , 98, 405-13	2.2	25

642	Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. <i>Blood</i> , 2001 , 98, 548-53	2.2	173
641	Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. <i>Blood</i> , 2001 , 98, 1302-11	2.2	370
640	Expression of high Km 5Mnucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. <i>Blood</i> , 2001 , 98, 1922-6	2.2	73
639	Acute Myelogenous Leukaemia in Patients 60 Years and Older: A Retrospective Analysis from St Bartholomew's Hospital 1969-1999. 2001 , 6, 163-75		1
638	Long-term follow-up of the clinical efficacy of chemotherapy for acute myeloid leukemia at a single institute. 2001 , 7, 156-62		3
637	Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. 2001 , 112, 118-26		137
636	Comparison of Sequential Versus Standard Chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. 2001 , 113, 713-26		78
635	Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. 2001 , 115, 25-33		63
634	Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. 2001 , 115, 257-62		69
633	Acute myeloid leukemia in the elderly: biology and therapeutic strategies. 2001 , 39, 275-87		55
632	Therapeutic options for acute myelogenous leukemia. 2001 , 92, 1059-73		79
631	Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?. 2001 , 30, 261-6		4
630	FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. <i>Blood</i> , 2001 , 97, 3589-95.2	2.2	361
629	A practical approach to the older patient with cancer. 2001 , 25, 7-76		23
628	Morphological diagnoses of the Japan adult leukemia study group acute myeloid leukemia protocols: central review. 2001 , 73, 93-9		15
627	MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7. 2001 , 15, 398-405		12
626	Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. 2001 , 15, 764-71		31
625	The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients. 2001 , 15, 903-9		57

624	CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. 2001 , 15, 1161-4	127
623	Clonality assay of hematopoietic disorders: significance of the buccal epithelium as non-hematopoietic control and of 95% rejection limit as a novel criterion for monoclonality. 2001 , 92, 1305-12	3
622	Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. 2001 , 25, 23-32	20
621	De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy. 2001 , 25, 33-38	9
620	Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. 2001 , 25, 685-92	10
619	High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. 2001 , 25, 875-81	31
618	Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia. 2001 , 66, 160-7	11
617	FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia. 2001 , 67, 221-9	7
616	Acute Leukemias VIII. <i>Hamatologie Und Bluttransfusion</i> , 2001 ,	1
615	Retinal abnormalities in newly diagnosed adult acute myeloid leukemia. 2001 , 105, 197-203	13
614	Immunophenotyping of Acute Leukaemias. Immunophänotypisierung akuter Leukämien. 2001 , 25, 512-532	
613	Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor. 2001 , 24, 58-63	10
612	The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study. 2001 , 29, 41-7	
611	Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. 2002 , 43, 1951-5	31
610	New therapies in leukemia: renewed hope. 2002 , 11, 583-7	
609	Acute myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2002 , 2002, 73-110	3.1 68
608	The World Health Organization (WHO) classification of the myeloid neoplasms. <i>Blood</i> , 2002 , 100, 2292-302	1637
607	The role of drug efflux pumps in acute myeloid leukemia. 2002 , 43, 685-701	71

606	Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr. 2002 , 69, 200-4		14
605	Prognostic factors in elderly patients with acute myelogenous leukemia: a single center study in Japan. 2002 , 43, 83-7		10
604	The outcomes and costs of acute myeloid leukemia among the elderly. 2002 , 162, 1597-603		217
603	Combination of mitoxantrone and etoposide in the Treatment of Advanced Myelodysplastic Syndrome/Secondary Acute Myeloid Leukemia - a Multicenter Phase II Study. 2002 , 23, 57-61		
602	Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. 2002 , 16, 813-9		82
601	Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). 2002 , 16, 833-9		140
600	[Diagnostics and therapy of acute myeloid leukemia]. 2002 , 127, 2208-13		
599	Is there an upper age limit for bone marrow transplantation?. 2002 , 29, 277-84		33
598	Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation. 2002 , 16, 799-812		50
597	Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. 2002 , 16, 581-6		18
596	Therapy of secondary leukemia. 2002 , 16, 748-50		18
595	The challenge of acute myeloid leukemia in older patients. 2002 , 14, 24-30		41
594	Clinical outcome in chordoma: utility of flow cytometry in DNA determination. 2002 , 27, 374-9		24
593	Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. <i>Blood</i> , 2002 , 100, 3869-76	2.2	153
592	Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. <i>Blood</i> , 2002 , 100, 29-35	2.2	66
591	P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. 2002 , 43, 1221-8		79
590	Rapid Cycle Real-Time PCR – Methods and Applications. 2002 ,		3
589	Acute myeloid leukaemia: optimising treatment in elderly patients. 2002 , 19, 571-81		11

588	The search for optimal treatment in relapsed and refractory acute myeloid leukemia. 2002 , 43, 281-91		27
587	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2002 , 100, 974-81	2.2	92
586	Treatment of acute myeloid leukemia: state-of-the-art and future directions. 2002 , 39, 4-10		24
585	MDR1 inhibition: less resistance or less relevance?. 2002 , 38, 2337-40		31
584	Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. <i>Blood</i> , 2002 , 100, 1910-1912	46	
583	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. <i>Blood</i> , 2002 , 100, 1224-1232	2.2	308
582	The difficult problem of acute myeloid leukemia in the older adult. 2002 , 52, 363-71		80
581	Compared to traditional protocols, newer induction schedules have limited benefits for older people with acute myeloid leukemia. 2002 , 3, 77-80		1
580	Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation. 2002 , 68, 54-63		15
579	Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation. 2002 , 68, 345-53		18
578	Acute myeloid leukemia: treatment over 60. 2002 , 6, 46-59; discussion 86-7		26
577	Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. 2002 , 30, 126-34		35
576	Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases. 2002 , 75, 45-50		11
575	Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemia. 2002 , 75, 519-27		1
574	Cytogenetics in acute myeloid leukemia. 2002 , 4, 390-7		43
573	Older adults with acute myeloid leukemia. 2002 , 4, 403-9		8
572	Internistisch-onkologische Therapie des geriatrischen Tumorpatienten. 2002 , 8, 114-127		
571	Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase Iâ study. 2002 , 116, 308-315		4

570	In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. 2002 , 117, 860-8	130
569	Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. 2002 , 26, 143-54	30
568	PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. 2002 , 26, 91-106	42
567	Clinical impact of multidrug resistance in acute leukemia. 2002 , 26, 323-5	1
566	Sphingosine kinase inhibitors in the apoptosis of leukaemia cells. 2002 , 26, 415-6	6
565	Clinical significance of IL-18 gene over-expression in AML. 2002 , 26, 887-92	23
564	Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). 2002 , 16, 1627-36	195
563	Transcription factor fusions in acute leukemia: variations on a theme. 2002 , 21, 3422-44	90
562	Mdr1 gene expression and mutations in Ras proto-oncogenes in acute myeloid leukemia. 2002 , 43, 1345-54	7
561	High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. 2003 , 82, 476-480	8
560	[Elderly patients with acute myeloid leukemia: characteristics in biology, patients, and treatment]. 2003 , 98, 193-207	1
559	New developments in antibody therapy for acute myeloid leukemia. 2003 , 30, 502-8	11
558	Acute myeloid leukemia in the older patient. 2003 , 48, S17-26	21
557	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. 2003 , 120, 281-8	80
556	Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications. 2003 , 120, 1009-16	22
555	Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival. 2003 , 123, 72-80	10
554	Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?. 2003 , 17, 488-91	9
553	Age-related changes of P-glycoprotein-mediated rhodamine 123 efflux in normal human bone marrow hematopoietic stem cells. 2003 , 17, 816-8	11

552	The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. 2003 , 17, 1538-43		36
551	Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. 2003 , 17, 2122-9		90
550	A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. 2003 , 27, 323-8		37
549	Farnesyl transferase inhibitors in myeloid malignancies. 2003 , 17, 123-9		20
548	Intensive care unit outcomes in elderly cancer patients. 2003 , 19, 657-75		7
547	Multidrug resistance reversal agents. 2003 , 46, 4805-17		262
546	Immunophenotyping as a guide for targeted therapy. 2003 , 16, 629-44		4
545	Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. 2003 , 20, 154-79		15
544	Epidemiology and clinical burden of acute myeloid leukemia. 2003 , 3, 695-710		23
543	Participation of patients 65 years of age or older in cancer clinical trials. 2003 , 21, 1383-9		800
542	Myelodysplastic syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2003 , 2003, 176-99	3.1	37
541	On the use of DNA methylation inhibitors and the reversal of transcriptional silencing. <i>Blood</i> , 2003 , 101, 1656; author reply 1657-8	2.2	6
540	The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. <i>Blood</i> , 2003 , 102, 4493-8	2.2	78
539	Management of acute myelogenous leukemia in the elderly. 2003 , 10, 469-77		18
538	Chemotherapy in the elderly: supportive measures for chemotherapy-induced myelotoxicity. 2003 , 7, 185-90		8
537	Investigational agents in myeloid disorders. 2004 , 51, 59-97		
536	Use of fludarabine in the treatment of acute myeloid leukemia. 2004 , 5 Suppl 1, S62-7		14
535	Principles of Molecular Oncology. 2004 ,		6

534	Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). 2004 , 22, 1078-86	198
533	Post-PCR Multiplex Fluorescent Ligation Detection Assay and Flow Cytometry for Rapid Detection of Gene-Specific Translocations in Leukemia. 2004 , 122, 783-793	13
532	Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. 2004 , 22, 262-8	114
531	A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m ² on days 1, 3, and 5). 2004 , 10, 3965-71	22
530	Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. 2004 , 22, 4290-301	134
529	Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG). 2004 , 27, 72-82	12
528	Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. 2004 , 9, 91-105	62
527	Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides. 2004 , 32, 4411-9	39
526	MDR1, chemotherapy and chromatin remodeling. 2004 , 3, 819-24	43
525	Progress in defining multidrug resistance in leukemia. 2004 , 4, 209-17	5
524	Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. 2004 , 10, 7896-902	158
523	Differentiation of acute myeloid leukemia from B- and T-lineage acute lymphoid leukemias by real-time quantitative reverse transcription-PCR of lineage marker mRNAs. 2004 , 50, 1165-73	9
522	Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. 2004 , 124, 474-80	23
521	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. 2004 , 125, 203-12	22
520	Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. 2004 , 33, 891-900	23
519	Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation. 2004 , 34, 573-6	13
518	Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. 2004 , 18, 809-16	160
517	Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. 2004 , 18, 1798-803	138

516	Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. 2004 , 72, 307-13		46
515	Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle. 2004 , 72, 38-44		6
514	Cytoprotection in acute myelogenous leukemia (AML) therapy. 2004 , 31, 67-73		14
513	Acute myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2004 , 2004, 98-117	3.1	164
512	Adult acute myeloid leukaemia. 2004 , 50, 197-222		126
511	Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 2004 , 83, 696-703		25
510	Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. 2004 , 53, 363-9		49
509	Changing picture of cellular drug resistance in human leukemia. 2004 , 50, 39-49		24
508	New agents in acute myeloid leukemia and other myeloid disorders. 2004 , 100, 441-54		34
507	Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia. 2004 , 28, 449-55		7
506	A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. 2004 , 28, 571-7		17
505	Problems related to resistance to cytarabine in acute myeloid leukemia. 2004 , 45, 1123-32		58
504	Mécanismes de résistance aux agents cytostatiques. 2004 , 1, 59-68		
503	Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. 2004 , 17, 641-651		29
502	Reversal of MDR by verapamil analogues. 2004 , 9, 47-56		7
501	The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. <i>Blood</i> , 2004 , 103, 4276-84	2.2	76
500	A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. <i>Blood</i> , 2004 , 103, 479-85	2.2	238
499	Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. <i>Blood</i> , 2004 , 104, 1940-51	2.2	128

498	Treatment of AML in biological subgroups. 2005 , 10 Suppl 1, 281-85		3
497	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. <i>Blood</i> , 2005 , 105, 1810-4	2.2	247
496	Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. <i>Blood</i> , 2005 , 106, 27-34	2.2	132
495	Drug therapy for acute myeloid leukemia. <i>Blood</i> , 2005 , 106, 1154-63	2.2	521
494	PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. <i>Blood</i> , 2005 , 106, 3584-93	2.2	47
493	The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. <i>Blood</i> , 2005 , 106, 2646-54	2.2	144
492	A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. 2005 , 29, 263-71		22
491	Trying to improve clinical outcome in AML: lessons from negative trials. 2005 , 29, 603-4		3
490	Treatment of older patients with AML. 2005 , 56, 247-59		31
489	Fas, Fas-associated death domain-like interleukin 1beta-converting enzyme-like inhibitory protein, and apoptotic features of elderly acute myeloid leukemia based on response to induction chemotherapy. 2005 , 82, 327-32		2
488	Hepatobiliary transporter expression in human hepatocellular carcinoma. 2005 , 25, 367-79		99
487	MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. 2005 , 128, 324-32		139
486	188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. 2005 , 130, 604-13		84
485	Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. 2005 , 13, 1768-73		78
484	Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. 2005 , 24, 8061-75		169
483	Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. 2005 , 103, 2082-90		75
482	Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. 2005 , 104, 101-9		86
481	Outcome of patients with acute myelogenous leukemia after second salvage therapy. 2005 , 104, 547-54		57

480	Leukemic transformation of polycythemia vera: a single center study of 23 patients. 2005 , 104, 1032-6	67
479	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. 2005 , 104, 1442-52	364
478	Advances in the molecular genetics of acute leukemia. 2005 , 7, 323-32	3
477	Cytogenetics of Hematologic Neoplasms. 2005 , 365-420	1
476	Biologically targeted therapies for myelodysplastic syndromes. 2005 , 173-208	
475	Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. 2005 , 23, 9387-93	197
474	Cyclosporin A is a broad-spectrum multidrug resistance modulator. 2005 , 11, 2320-6	189
473	Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. 2005 , 46, 367-75	7
472	Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated. 2005 , 46, 401-4	1
471	Inhibitors of DNA methylation: beyond myelodysplastic syndromes. 2005 , 2 Suppl 1, S36-44	52
470	The Principles of Clinical Cytogenetics. 2005 ,	25
469	Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes. 2005 , 114, 78-83	14
468	Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. 2005 , 16, 1366-73	39
467	New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. <i>Hematology American Society of Hematology Education Program</i> , 2005 , 2005, 143-50	3.1 52
466	MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. 2005 , 11, 7764-72	131
465	Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia. 2005 , 46, 63-70	5
464	Treatment of elderly cancer patients with chemotherapy. 2005 , 23, 537-47	9
463	[Treatment of cancer and hematological malignancy in elderly people (Part II)]. 2005 , 26, 304-14	2

462	Trends in the treatment of acute myeloid leukaemia in the elderly. 2005 , 22, 943-55		66
461	Cancer Drug Resistance. 2006 ,		17
460	Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia. 2006 , 47, 461-7		24
459	The role of post-remission chemotherapy for older patients with acute myelogenous leukemia. 2006 , 47, 689-95		10
458	Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group. 2006 , 47, 697-706		3
457	Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. 2006 , 47, 425-32		5
456	Identification of novel genes with prognostic value in childhood leukemia using cDNA microarray and quantitative RT-PCR. 2006 , 23, 115-27		8
455	Approach to the complications of treatment for acute leukemia in the elderly. 2006 , 43, 134-43		5
454	Treatment of older patients with acute myeloid leukemia--new agents. 2006 , 43, 96-106		43
453	Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. 2006 , 24, 444-53		220
452	Adult acute myeloid leukemia. 2006 , 81, 247-60		90
451	Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. 2006 , 19, 825-38		27
450	Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. <i>Blood</i> , 2006 , 107, 1315-24	2.2	62
449	XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report. <i>Blood</i> , 2006 , 107, 39-45	2.2	29
448	Age and acute myeloid leukemia. <i>Blood</i> , 2006 , 107, 3481-5	2.2	941
447	Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. <i>Blood</i> , 2006 , 108, 63-73	2.2	253
446	Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. <i>Blood</i> , 2006 , 108, 3280-8	2.2	234
445	Pronostic et traitement des leucémies aiguës myéloblastiques. 2006 , 1, 1-13		

444	Treatment of relapsed acute myeloid leukaemia. 2006 , 1, 103-11	23
443	Mechanisms de résistance aux agents cytostatiques. 2006 , 1, 1-7	
442	Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. 2006 , 132, 755-69	49
441	Current therapeutic strategies for acute myeloid leukaemia. 2006 , 134, 555-72	23
440	Guidelines on the management of acute myeloid leukaemia in adults. 2006 , 135, 450-74	109
439	Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). 2006 , 37, 547-52	14
438	Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. 2006 , 20, 42-7	63
437	Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials. 2006 , 20, 2169-71	18
436	ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. 2006 , 80, 427-39	36
435	Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. 2006 , 30, 1-8	23
434	Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. 2006 , 30, 407-13	58
433	The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). 2006 , 30, 801-11	42
432	A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. 2006 , 30, 777-83	65
431	Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. 2006 , 30, 813-22	43
430	Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?. 2006 , 30, 1077-8	6
429	Genes of multidrug resistance in haematological malignancies. 2006 , 61, 247-256	3
428	Impairment in functional status and survival in patients with acute myeloid leukaemia. 2006 , 132, 665-71	73
427	Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. 2006 , 85, 250-6	17

426	Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia. 2006 , 85, 357-65	5
425	Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells. 2006 , 57, 517-24	2
424	Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes. 2006 , 81, 249-54	10
423	Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. 2006 , 76, 409-13	22
422	Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation. 2006 , 34, 1360-76	27
421	Phase III study of PSC-833 (valsopodar) in combination with vincristine, doxorubicin, and dexamethasone (valsopodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. 2006 , 106, 830-8	100
420	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. 2006 , 106, 1090-8	478
419	Treatment of acute myelogenous leukemia with outpatient azacitidine. 2006 , 107, 1839-43	67
418	Acute myeloid leukemia: epidemiology and etiology. 2006 , 107, 2099-107	420
417	Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase. 2006 , 8, 972-9	11
416	Monoclonal antibodies for the treatment of acute myeloid leukemia. 2006 , 7, 343-69	26
415	Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. 2006 , 17, 281-5	27
414	Treatment of acute myeloid leukemia patients aged more than 75 years: results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). 2006 , 47, 2062-9	13
413	Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia. 2006 , 12, 7018-24	20
412	Unrelated cord blood allogeneic stem cell transplantation for MDS. 2006 , 47, 569-70	2
411	Cancer du sujet âgé. 2007 ,	
410	Treatment of acute myeloid leukemia in older patients. 2007 , 7, 285-95	20
409	Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. 2007 , 127, 197-205	73

408	Drug resistance and methylation in myelodysplastic syndrome. 2007 , 8, 77-81		3
407	Prognostic factors in elderly patients with AML and the implications for treatment. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 420-8	3-1	39
406	Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. 2007 , 12, 393-401		15
405	White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. 2007 , 48, 1561-8		12
404	Acute myeloid leukemia and myelodysplastic syndromes in older patients. 2007 , 25, 1908-15		197
403	Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. 2007 , 12, 341-55		79
402	Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. 2007 , 117, 8-15		33
401	A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. <i>Blood</i> , 2007 , 109, 1387-94	2.2	163
400	Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. <i>Blood</i> , 2007 , 109, 3936-44	2.2	42
399	End points to establish the efficacy of new agents in the treatment of acute leukemia. <i>Blood</i> , 2007 , 109, 1810-6	2.2	74
398	CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. <i>Blood</i> , 2007 , 109, 4168-70	2.2	150
397	Multidrug Resistance Protein: P-Glycoprotein. 223-262		13
396	Tolerance to chemotherapy in elderly patients with cancer. 2007 , 14, 44-56		72
395	Acute Myelogenous Leukemia. 2007 ,		
394	Molecular mechanisms of drug resistance in acute myeloid leukaemia. 2007 , 3, 363-77		14
393	Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. 2007 , 25, 4246-54		320
392	[Retinal abnormalities in adult acute myeloid leukemia: semeiological features and prognostic correlations. Analysis of 178 cases]. 2007 , 30, 819-23		1
391	Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. 2007 , 46, 449-70		81

390	Lymphomes et autres tumeurs h�matologiques. 2007 , 179-206	1
389	Management of Haematological Malignancies. 2007 ,	1
388	Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. 2007 , 92, 389-96	42
387	Acute myeloid leukemia in the elderly. 237-255	
386	Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. 2007 , 25, 170-7	7
385	Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. 2007 , 110, 345-52	92
384	Allogeneic hematopoietic stem cell transplantation in the elderly. 2007 , 64, 49-63	27
383	HIC gene, a candidate suppressor gene within a minimal region of loss at 7q31.1 in myeloid neoplasms. 2007 , 31, 477-82	22
382	Blood and marrow transplantation in elderly acute myeloid leukaemia patients - older certainly is not better. 2007 , 40, 405-16	17
381	High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. 2007 , 21, 66-71	207
380	Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. 2007 , 21, 427-38	151
379	The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. 2007 , 21, 739-46	30
378	ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?. 2007 , 21, 1172-6	104
377	ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. 2007 , 21, 2094-102	77
376	Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. 2007 , 138, 186-95	34
375	Complex karyotypes confer a poor survival in adult acute myeloid leukemia with unfavorable cytogenetic abnormalities. 2007 , 174, 138-46	11
374	P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors. 2007 , 35, 1793-800	21
373	Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. 2007 , 12, 838-43	52

372	Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. 2007 , 78, 477-86	17
371	Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older. 2007 , 79, 398-404	13
370	Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22). 2007 , 24, 907-20	4
369	[Diagnostics, classification and prognostic criteria of acute myeloid leukemia]. 2007 , 102, 296-308	0
368	[Therapy of acute myeloid leukemia (AML) for medically non-fit patients]. 2007 , 102, 324-9	4
367	CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. 2007 , 86, 329-37	84
366	Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. 2007 , 60, 179-88	66
365	Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. 2007 , 60, 245-55	60
364	ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. 2007 , 62, 214-26	73
363	Bertherapie in der Onkologie: Wann ist weniger mehr?. 2008 , 14, 691-700	3
362	Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. 2008 , 112, 572-80	36
361	Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. 2008 , 26, 33-8	6
360	Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. 2008 , 32, 465-73	29
359	The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. 2008 , 32, 1698-708	19
358	Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. 2008 , 22, 221-34	36
357	Induction therapy for elderly patients with acute myeloid leukemia. 2008 , 22, 311-20	14
356	Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?. 2008 , 41, 935-40	28
355	Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. 2008 , 41, 415-23	36

354	Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. 2008 , 143, 681-9		50
353	Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). 2008 , 8, 51		44
352	Acute myeloid leukemia in the elderly. 2008 , 35, 430-8		54
351	Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. 2008 , 80, 208-15		61
350	What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?. 2008 , 21, 667-75		18
349	Acute Myeloid Leukemia in Older Patients: Special Problems and Possible Solutions. 2008 , 2, 237-240		
348	Prognostic Factors in Elderly Patients with Acute Myeloid Leukemia: Trying to Make the Best of a Bad Situation. 2008 , 2, 174-181		0
347	Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. 2008 , 49, 994-7		8
346	Current and emerging strategies for the management of acute myeloid leukemia in the elderly. 2008 , 13, 1097-108		21
345	Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. 2008 , 19, 128-34		22
344	Leukemia and Lymphoma Immunophenotyping and Cytogenetics. 2008 , 221-256		
343	MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. <i>Blood</i> , 2008 , 111, 1855-61	2.2	54
342	High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. <i>Blood</i> , 2008 , 111, 5371-9	2.2	159
341	Optimizing therapy for acute myeloid leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008 , 6, 1003-16	7.3	15
340	Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. 2008 , 93, 662-9		76
339	Orbital and ocular manifestations of acute childhood leukemia: clinical and statistical analysis of 180 patients. 2008 , 18, 619-23		68
338	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. 2009 , 4, 197-205		14
337	. 2009 ,		9

336	Late Effects of Treatment for Brain Tumors. 2009 ,	4
335	Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. 2009 , 27, 61-9	271
334	What is the role of reduced-intensity transplantation in the treatment of older patients with AML?. <i>Hematology American Society of Hematology Education Program</i> , 2009 , 406-13	3.1 10
333	Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. 2009 , 1, 481-90	32
332	Clofarabine: a new treatment option for patients with acute myeloid leukemia. 2009 , 10, 1353-7	1
331	Management of the older patient. 2009 , 303-312	
330	Acute myelogenous leukemia in older adults. 2009 , 14, 222-32	76
329	P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. 2009 , 9, 199	36
328	A single-center population-based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender. 1999 , 62, 95-102	44
327	Leukaemia cell drug resistance and prognostic factors in AML. 1999 , 63, 219-24	12
326	Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. 2009 , 27, 148-53	37
325	Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. 2009 , 115, 2922-9	24
324	Immunophenotypic profile of acute leukemia: critical analysis and insights gained at a tertiary care center in India. 2009 , 76, 199-205	12
323	New drugs in the treatment of acute myeloid leukaemia. 2009 , 2, 75-79	0
322	Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. 2009 , 88, 151-8	24
321	Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. 2009 , 145, 598-605	192
320	Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia. 2009 , 145, 648-56	21
319	A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. 2009 , 33, 1055-61	40

318	Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. 2009 , 33, 769-74		12
317	Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. 2009 , 35, 97-120		47
316	Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia. 2009 , 63, 566-70		11
315	Selenite is a potent cytotoxic agent for human primary AML cells. 2009 , 282, 116-23		36
314	Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence?. 2009 , 9, 289-97		5
313	Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia. 2009 , 3, 14-19		
312	Acute leukemia in patients sixty years of age and older: a twenty year single institution review. 2009 , 32, 137-41		4
311	Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. <i>Blood</i> , 2009 , 113, 866-74	2.2	55
310	Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. <i>Blood</i> , 2009 , 113, 3666-72	2.2	99
309	A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. <i>Blood</i> , 2009 , 114, 1166-73	2.2	113
308	AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. <i>Blood</i> , 2009 , 114, 2869-77	2.2	36
307	Expression, Detection, and Implication of ABC Proteins in Acute Myeloblastic Leukemia. 119-141		
306	Novel postremission strategies in adults with acute myeloid leukemia. 2009 , 16, 105-11		8
305	Low SMC1A protein expression predicts poor survival in acute myeloid leukemia. 2010 , 24, 47-56		14
304	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. <i>Blood</i> , 2010 , 116, 4422-9	2.2	280
303	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010 , 115, 453-74	2.2	2483
302	Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia. 2010 , 5, 95-100		8
301	Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. 2010 , 116, 5012-21		83

300	Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. 2010 , 34, 487-91	12
299	Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. 2010 , 148, 48-58	24
298	Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study. 2010 , 148, 918-24	18
297	Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. 2010 , 24, 909-13	83
296	A Hypothetical-Mathematical Model of Acute Myeloid Leukaemia Pathogenesis. 2010 , 11, 49-65	9
295	Hematopoietic cell transplantation in older adults. 260-273	4
294	Challenges in treating older patients with acute myeloid leukemia. 2010 , 2010, 943823	25
293	Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic. 2010 , 57, 578-89	5
292	Traitement des leucémies aiguës myéloïdes de l'adulte. 2010 , 16, 21-23	
291	The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. 2010 , 9, 661-72	34
290	Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. 2010 , 28, 549-55	185
289	Older patients with acute myeloid leukemia. 2010 , 3, 755-74	2
288	Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. 2010 , 28, 1878-87	385
287	Acute Myeloid Leukemia. 2010 , 45-139	1
286	Acute Myeloid Leukemia With Myelodysplasia-Related Changes: A New Definition. 2010 , 3, 1153-64	11
285	A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity. 2010 , 5, 065002	47
284	Has there been progress in the treatment of older patients with acute myeloid leukemia?. 2010 , 23, 495-501	13
283	Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. <i>Blood</i> , 2010 , 116, 4077-85	2.2 157

282	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010 , 116, 5660-9	2.2	99
281	Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. 2010 , 28, 596-604		268
280	Amonafide: a potential role in treating acute myeloid leukemia. 2011 , 20, 995-1003		13
279	Therapeutics formulated to target cancer stem cells: Is it in our future?. 2011 , 11, 7		25
278	Childhood Leukemia. 2011 ,		6
277	Aging of hematopoietic stem cells: Intrinsic changes or micro-environmental effects?. 2011 , 23, 512-7		48
276	Exercise for older adult inpatients with acute myelogenous leukemia: A pilot study. 2011 , 2, 11-17		51
275	Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia. 2011 , 2, 215-221		5
274	The effect of chemotherapy, detection of minimal residual disease, and hematopoietic stem cell transplantation. 357-378		
273	Identifying older patients with acute myeloid leukemia who may be candidates for reduced-intensity hematopoietic cell transplantation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 319-29; quiz 330	7.3	3
272	A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. <i>Blood</i> , 2011 , 118, 523-8	2.2	69
271	Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 4188-98	2.2	48
270	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 6030-6	2.2	85
269	Novel agents for the treatment of acute myeloid leukemia in the older patient. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 331-5	7.3	13
268	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. 2011 , 18, 237-45		30
267	Clinical results and issues of acute myeloid leukemia in elderly patients aged 75 years and older. 2011 , 11, 290-6		4
266	Acute myeloid leukaemia in the elderly: a review. 2011 , 152, 524-42		108
265	Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. 2011 , 25, 420-8		29

264	Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 2164-75	5.6	130
263	A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. 2011 , 35, 1384-9		42
262	A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. 2011 , 33, 254-79		26
261	Unfavorable-risk cytogenetics in acute myeloid leukemia. 2011 , 4, 173-84		14
260	Upfront therapy of acute myeloid leukemia. 2011 , 13, 361-70		2
259	P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. 2011 , 11, 254		13
258	A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 2011 , 117, 1253-61		26
257	Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. 2011 , 117, 2156-62		19
256	Diffuse large B-cell lymphoma in the older. 2011 , 78, 59-72		8
255	Up-regulation of ABCB1/P-glycoprotein by escaping promoter hypermethylation indicates poor prognosis in hematologic malignancy patients with and without bone marrow transplantation. 2011 , 35, 73-9		9
254	Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. 2011 , 96, 696-702		51
253	Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial. 2011 , 1, e23		7
252	Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience. 2011 , 41, 820-4		2
251	Diagnosis and management of haematological malignancies in older people. 2011 , 21, 297-311		
250	A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. 2011 , 25, 1808-14		39
249	Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. 2011 , 25, 800-7		22
248	Revisiting the ABCs of multidrug resistance in cancer chemotherapy. 2011 , 12, 570-94		155
247	Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia. 2011 , 46, 1256-62		6

- 246 Similarities and differences between therapy-related and elderly acute myeloid leukemia. **2011**, 3, e2011052 6
- 245 Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults. **2012**, 46, 89-96 10
- 244 Anthracycline dose intensification in young adults with acute myeloid leukemia. **2012**, 3, 17-27 7
- 243 Erlotinib antagonizes ABC transporters in acute myeloid leukemia. **2012**, 11, 4079-92 45
- 242 New treatment approaches in acute myeloid leukemia: review of recent clinical studies. **2012**, 7, 224-37 6
- 241 Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation. **2012**, 82, 1008-21 71
- 240 [Effectiveness and safety of the FLAG-IDA regimen in acute refractory or recurrent leukaemia]. **2012**, 36, 261-7 2
- 239 A highly sensitive resonance scattering based sensor using unmodified gold nanoparticles for daunomycin detection in aqueous solution. **2012**, 4, 2266 12
- 238 New agents for acute myeloid leukemia: is it time for targeted therapies?. **2012**, 21, 179-89 15
- 237 Microparticles and their emerging role in cancer multidrug resistance. **2012**, 38, 226-34 121
- 236 Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?. **2012**, 5, 17-26 13
- 235 Treatment decisions for elderly patients with haematological malignancies: a dilemma. **2012**, 13, e344-52 34
- 234 Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML. **2012**, 3, 220-227 1
- 233 Management of Myelodysplastic Syndromes and Acute Leukaemia. **2012**, 375-385
- 232 Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results. **2012**, 29, 2070-6
- 231 Liquid tumors in the elderly. **2012**, 28, 115-52
- 230 Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. **2012**, 70, 461-9 47
- 229 Prognosis and Survival in Acute Myelogenous Leukemia. **2012**, 2

228	Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. 2012 , 53, 110-7	78
227	ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients. 2012 , 138, 959-69	13
226	Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. 2012 , 92, 44-9	40
225	Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. 2012 , 118, 1014-22	96
224	Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. 2012 , 87, 37-41	20
223	Cancer stem cells and therapeutic targets: an emerging field for cancer treatment. 2013 , 3, 113-20	17
222	Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies. 2013 , 30, 373-81	9
221	De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". 2013 , 92, 1309-18	3
220	Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. 2013 , 119, 2720-7	135
219	Inventory and general analysis of the ATP-binding cassette (ABC) gene superfamily in maize (<i>Zea mays</i> L.). 2013 , 526, 411-28	48
218	Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. 2013 , 6, 547-62	23
217	Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis. 2013 , 27, 2149-56	11
216	Molecular pharmacology of ABCG2 and its role in chemoresistance. 2013 , 84, 655-69	152
215	The evolving landscape in the therapy of acute myeloid leukemia. 2013 , 4, 735-46	19
214	A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. 2013 , 37, 1502-8	16
213	Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. 2013 , 65, 1731-47	189
212	Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?. 2013 , 32, 211-27	98
211	Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. 2013 , 88, 10-5	13

210	Ostra biańczka szpikowa u osób w wieku podeszłym. 2013 , 44, 75-84		1
209	Immunobiology of Acute Leukemia. 2013 , 241-283		
208	Acute myeloid leukaemia in adults. 2013 , 381, 484-95		360
207	Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. 2013 , 6, 767-84		22
206	Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?. 2013 , 38, 73-84		12
205	Medical emergency team involvement in patients hospitalized with acute myeloid leukemia. 2013 , 54, 2236-42		6
204	Is there a role for metronomic induction (and maintenance) therapy in elderly patients with acute myeloid leukemia? A literature review. 2013 , 50, 154-8		11
203	Clofarabine in the treatment of acute myeloid leukemia in older adults. 2013 , 4, 5-13		8
202	Update on optimal management of acute myeloid leukemia. 2013 , 7, 181-97		10
201	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. <i>Blood</i> , 2013 , 122, 1455-63	2.2	313
200	Successful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reports. 2013 , 5, 1321-1324		6
199	Deregulation of mitochondrial ATPsyn- β in acute myeloid leukemia cells and with increased drug resistance. 2013 , 8, e83610		14
198	Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients. 2014 , 9, 753-62		9
197	Decitabine in the treatment of acute myeloid leukemia in elderly patients. 2014 , 6, 53-61		45
196	Do ABC proteins still have a role to play in acute myeloid leukemia?. 2014 , 20, 264-275		
195	Immunotherapy in acute myeloid leukemia. 2014 , 6, 95-106		25
194	Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype. 2014 , 167, 671-80		10
193	Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. 2014 , 7, 439-64		16

192	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. 2014 , 111, 18679-84		181
191	The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q). 2014 , 166, 550-6		26
190	The epigenetic landscape of acute myeloid leukemia. 2014 , 2014, 103175		61
189	Acute myeloid leukemia in the elderly: do we know who should be treated and how?. 2014 , 55, 979-87		29
188	Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients. 2014 , 10, 246-54		4
187	Ultra-low-dose decitabine combined with autologous cytokine-induced killer cells for elderly patients with acute myeloid leukemia transformed from myelodysplastic syndrome. 2014 , 36, 1104-11		6
186	FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia. 2014 , 93, 577-93		14
185	Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. 2014 , 20, 816-22		70
184	Nowe strategie leczenia zespołu mielodysplastycznych wysokiego ryzyka. 2014 , 45, 240-246		
183	Długostrwała odpowiedź na leczenie azacytydyną pacjentki z ostrą białą krwią z niekorzystnym profilem cytogenetycznym – prezentacja przypadku. 2014 , 45, 93-96		
182	Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. 2014 , 10, 655-69		26
181	Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. <i>Blood</i> , 2014 , 123, 3239-46	2.2	252
180	From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation. <i>Blood</i> , 2015 , 126, 2561-9	2.2	71
179	Prognostic impact of CD56 in pediatric AML. 2015 , 37, e157-9		2
178	Nonbiological factors affecting survival in younger patients with acute myeloid leukemia. 2015 , 121, 3877-84		35
177	Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India. 2015 , 11, 242-52		18
176	Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study. 2015 , 90, 904-9		3
175	Identification of prognostic subgroups among acute myeloid leukemia patients with intermediate risk cytogenetics using a flow-cytometry-based assessment of ABC-transporter function. 2015 , 39, 689-95		6

174	Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. 2015 , 15, 109-18	19
173	Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. 2015 , 56, 2331-8	8
172	Early mortality in acute myeloid leukemia. 2015 , 39, 505-9	14
171	How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 646-54	2 8
170	Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). 2015 , 94, 1981-9	9
169	Outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with monosomal karyotypes. 2015 , 133, 327-35	3
168	Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. 2015 , 32, 623-37	14
167	Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells. 2016 , 7, 845-59	18
166	How can nanomedicines overcome cellular-based anticancer drug resistance?. 2016 , 4, 5078-5100	29
165	Inclusion of elderly patients in oncology clinical trials. 2016 , 27, 1799-804	64
164	The effects of proliferation and DNA damage on hematopoietic stem cell function determine aging. 2016 , 245, 739-50	8
163	Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy. 2016 , 91, 1239-1245	9
162	Acute myeloid leukemia in the older adults. 2016 , 6, 1-7	82
161	The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy. 2016 , 95, e4182	11
160	Great expectations in acute myeloid leukemia. 2016 , 12, 289-92	
159	Long noncoding RNAs in hematopoietic malignancies. 2016 , 15, 227-38	14
158	Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly. 2016 , 32, 155-73	27
157	Predicting Chemotherapy Resistance in AML. 2017 , 12, 530-536	13

156	Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in -Rearranged Leukemia. 2017 , 16, 1669-1679	34
155	Innovative strategies for adverse karyotype acute myeloid leukemia. 2017 , 24, 89-98	2
154	Prolonged intracellular accumulation of light-inducible nanoparticles in leukemia cells allows their remote activation. 2017 , 8, 15204	12
153	Overexpression of long non-coding RNA zinc finger antisense 1 in acute myeloid leukemia cell lines influences cell growth and apoptosis. 2017 , 14, 647-651	18
152	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. 2017 , 59, 55-64	15
151	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. 2017 , 123, 3050-3060	39
150	Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study. 2017 , 35, 387-393	29
149	The management and treatment of acute leukemias in the elderly population. 2017 , 10, 975-985	4
148	Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥80 years. 2017 , 92, E567-E574	5
147	CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?. 2017 , 10, 853-862	19
146	ASXL1 mutations are frequent in de novo AML with trisomy 8 and confer an unfavorable prognosis. 2017 , 58, 204-206	6
145	Selecting initial treatment of acute myeloid leukaemia in older adults. 2017 , 31, 43-62	58
144	Outcomes of patients ≥85 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. 2017 , 140, 208-215	7
143	Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges. 2017 , 23, 4303-4310	4
142	Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-Asparaginase. 2017 , 8, 109915-109923	17
141	Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation. 2018 , 67, 99-108	15
140	Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. 2018 , 21, 556-563	20
139	Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. 2018 , 52, 55-62	6

138	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. 2018 , 36, 2684-2692		446
137	Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply. 2018 , 103, 1758-1759		4
136	Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes. 2018 , 17, 2575-2585		9
135	Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 63	5-4	10
134	Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy. 2018 , 2, 831-840		143
133	How I treat older patients with acute myeloid leukemia. 2018 , 124, 2472-2483		5
132	Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e287-e294	2	4
131	Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). 2018 , 7, 51-53		11
130	Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy. 2018 , 37, 88		20
129	Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. 2019 , 37, 447-455		11
128	Clinical outcomes in allogeneic haematopoietic stem cell transplantation: A comparison between young and elderly patients. Observational study. 2019 , 28, e13122		1
127	Long-term cardiac-specific mortality among 44,292 acute myeloid leukemia patients treated with chemotherapy: a population-based analysis. 2019 , 10, 6161-6169		2
126	Lung resistance-related protein (LRP) predicts favorable therapeutic outcome in Acute Myeloid Leukemia. 2019 , 9, 378		6
125	Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. 2019 , 12, 51		87
124	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. 2019 , 33, 2599-2609		36
123	Mechanisms of drug resistance in acute myeloid leukemia. 2019 , 12, 1937-1945		78
122	Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia. 2019 , 41, 461-471		4
121	Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF- κ B-dependent P-glycoprotein upregulation. 2019 , 60, 1078-1086		20

120	FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. 2019 , 67-88		0
119	Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials. 2019 , 77, 30-33		6
118	Top 100 Most Influential Articles in the Field of Myeloid Neoplasms: A Bibliometric Study. 2019 , 141, 68-78		5
117	Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. 2019 , 96, 57-66		7
116	Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. 2020 , 105, 398-406		20
115	ABC-transporters and drug efflux in hematologic cancers. 2020 , 149-195		1
114	Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. 2020 , 12,		17
113	Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. 2020 , 61, 631-640		7
112	Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible. <i>Frontiers in Oncology</i> , 2020 , 10, 1746	5:3	1
111	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. 2020 , 10, 96		9
110	Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 804-812.e8 ²		7
109	Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML. 2020 , 4, 5040-5049		2
108	Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial. 2020 , 38, 531-540		1
107	P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications. 2020 , 42, 594-603		9
106	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. 2020 , 34, 2914-2924		2
105	Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia. 2020 , 61, 1305-1312		2
104	Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. 2020 , 61, 1188-1194		5
103	How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective. 2020 , 16, 281-291		3

102	Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation. 2020 , 43, 100670	6
101	Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation. 2020 , 22, 4	4
100	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. 2020 , 93, 106367	11
99	Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment. 2020 , 37, 2288-2302	
98	Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences. 2021 , 46, 100735	4
97	Prognostic Factors in AML. <i>Hematologic Malignancies</i> , 2021 , 127-175	0 1
96	Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplant. 2021 , 231-250	
95	Improved Survival of Leukemic Mice Treated with Sodium Caseinate in Combination with Daunorubicin without Toxicity. 2021 , 2021, 6635650	
94	Molecular Subtyping and Outlier Detection in Human Disease Using the Paraclique Algorithm. 2021 , 14, 63	
93	Focus on Novel Therapies for Older Adults with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes. 2021 , 1, 237-248	0
92	Interactions between cardiology and oncology drugs in precision cardio-oncology. 2021 , 135, 1333-1351	2
91	Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells. 2021 , 510, 37-47	2
90	Rutaecarpine Increases Anticancer Drug Sensitivity in Drug-Resistant Cells through MARCH8-Dependent ABCB1 Degradation. 2021 , 9,	0
89	Acute Myeloid Leukemia and the Myelodysplastic Syndromes. 2006 , 1160-1181	1
88	Mechanisms of drug resistance in AML. 2002 , 112, 237-62	15
87	MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents. 2002 , 112, 49-66	25
86	MDR1/P-GP expression as a prognostic factor in acute leukemias. 1999 , 457, 1-9	32
85	Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts. 1999 , 457, 77-88	10

84	Discordance of P-glycoprotein expression and function in acute leukemia. 1999 , 457, 107-18		12
83	Clinical significance of P-glycoprotein (P-gp) expression in childhood acute lymphoblastic leukemia. Results of a 6-year prospective study. 1999 , 457, 11-9		6
82	Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia. 1999 , 457, 57-63		4
81	Molecular Pathways of Drug Resistance. 2004 , 463-489		1
80	Acute Myeloid Leukemia in Older Adults. 2020 , 501-520		1
79	Pharmacogenetic and Pharmacogenomic Considerations in the Biology and Treatment of Childhood Leukemia. 2011 , 163-189		1
78	Chromosome Aberrations in Primary and Secondary Acute Myeloblastic Leukemia (AML). <i>Hamatologie Und Bluttransfusion</i> , 2001 , 49-53		1
77	Chemotherapy and All-Trans Retinoic Acid in Patients >60 Years with Acute Myeloid Leukemia: First Results of the Multicenter Treatment Trial AML HD98-B. <i>Hamatologie Und Bluttransfusion</i> , 2001 , 604-608		2
76	Secondary neoplasms following treatment for brain tumors. 2009 , 150, 239-73		5
75	Acute Myeloid Leukemia in Adults. 2008 , 2215-2234		1
74	Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto. 2000 , 111, 334-7		13
73	Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia. 2000 , 111, 565-9		9
72	A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia. 2020 , 130, 1217-1232		13
71	Achievements in Understanding and Treatment of Myelodysplastic Syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 110-132	3.1	2
70	Achievements in Understanding and Treatment of Myelodysplastic Syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 110-132	3.1	3
69	A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031). <i>Blood</i> , 1998 , 91, 3607-3615	2.2	5
68	Pgp and MRP Activities Using Calcein-AM Are Prognostic Factors in Adult Acute Myeloid Leukemia Patients. <i>Blood</i> , 1998 , 91, 4480-4488	2.2	8
67	Hypomethylation Status of CpG Sites at the Promoter Region and Overexpression of the Human MDR1 Gene in Acute Myeloid Leukemias. <i>Blood</i> , 1998 , 92, 4296-4307	2.2	8

66	Prognostic Value of Cytogenetics and Multidrug Resistance (MDR1) in Elderly Patients With Acute Myeloid Leukemia. <i>Blood</i> , 1998 , 92, 695-697	2.2	9
65	Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar). <i>Blood</i> , 1999 , 93, 787-795	2.2	5
64	Microsatellite Instability and p53 Mutations Are Associated With Abnormal Expression of the MSH2 Gene in Adult Acute Leukemia. <i>Blood</i> , 1999 , 94, 733-740	2.2	3
63	The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. <i>Blood</i> , 2000 , 96, 870-877	2.2	3
62	How I treat older patients with AML. <i>Blood</i> , 2000 , 96, 1670-1673	2.2	2
61	Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly. 2019 , 17, eAE4340		2
60	Acute lymphoblastic leukemia in elderly patients: a single institution experience. 2011 , 26, 328-39		6
59	Clofarabine in the treatment of elderly patients with acute myeloid leukemia. 2013 , 14, 1089-92		2
58	Molecular target therapy of AKT and NF- κ B signaling pathways and multidrug resistance by specific cell penetrating inhibitor peptides in HL-60 cells. 2014 , 15, 4353-8		44
57	Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. 2021 ,		5
56	Treatment of Older Patients with Acute Myeloid Leukemia (AML). <i>Hamatologie Und Bluttransfusion</i> , 2001 , 611-620		
55	Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refractory and Relapsed Acute Myeloid Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 2001 , 578-587		
54	In-Vitro Cellular Drug Resistance in Acute Non-Lymphoblastic Leukemia: Comparisons Between Adults and Children. <i>Hamatologie Und Bluttransfusion</i> , 2001 , 244-250		
53	Stellenwert molekularbiologischer Verfahren in der klinischen Hämatologie und Onkologie. 2001 , 345-361		
52	Treatment of Older Adults with Acute Myelogenous Leukemia: Studies of the Eastern Cooperative Oncology Group (ECOG). <i>Hamatologie Und Bluttransfusion</i> , 2001 , 639-643		
51	Therapy of Older Adults with AML: CALGB Studies. <i>Hamatologie Und Bluttransfusion</i> , 2001 , 631-638		
50	Phase I Study of Liposomal Daunorubicin (DaunoXome) in Relapsed and Refractory Acute Myeloid Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 2001 , 191-195		
49	Measurement of MDR1 Gene Expression by Real-Time Quantitative RT-PCR Using the LightCycler Instrument. 2002 , 199-205		

- 48 Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia. **2003**, 13-27
- 47 [Acute myelocytic leukemia (M0) in an elderly patient with relapsed granulocytic sarcoma (M7) of bone during the second period of complete remission 5 years after onset]. *Japanese Journal of Geriatrics*, **2003**, 40, 176-81 ○
- 46 Myelodysplastische Syndrome. **2003**, 268-311
- 45 Single-Center Retrospective Analysis of Prognosis of 138 Patients Older than 55 Years with Acute Myeloid Leukemia. *Hamatologie Und Bluttransfusion*, **2003**, 312-320
- 44 Acute Myeloid Leukemia in Elderly Patients: Prognostic Value of Bone Marrow Aspirate on 14th Day of Induction Treatment. *Hamatologie Und Bluttransfusion*, **2003**, 321-326
- 43 No Evidence of MDR1 Gene Related Clonal Selection in Relapsed or Refractory Acute Myeloid Leukemia (AML). *Hamatologie Und Bluttransfusion*, **2003**, 220-231
- 42 Feasibility of High Dose Melphalan (140 mg/m²) and Peripheral Blood Stem Cell Support as Consolidation for Patients over 60 Years with Acute Myeloid Leukemia in First Complete Remission. *Hamatologie Und Bluttransfusion*, **2003**, 533-537
- 41 Investigational Therapy in Acute Myeloid Leukemia: 2001. *Hamatologie Und Bluttransfusion*, **2003**, 161-164
- 40 The Multidrug Resistance and Apoptosis Evaluation in Acute Myeloid Leukemia Cells After the In Vitro Doxorubicin Treatment. *Acta Medica (Hradec Kralove)*, **2004**, 47, 181-185 ○.8 2
- 39 Acute Myeloid Leukemia (AML)âCytogenetic Detection of Selected Recurrent Chromosomal Abnormalities. **2004**, 17-24
- 38 Hematopoietic Stem Cells, Aging, and Cancer. **2005**, 105-123
- 37 AML in Older Adults. **2007**, 373-384
- 36 Approaching the Treatment of AML from a Biological Perspective. **2007**, 3-23
- 35 World Health Organization Classification of Hematologic Malignancies. **2008**, 2131-2137
- 34 Hematologic malignancies: correlation between morphology, phenotype,. **2008**, 125-242
- 33 Molecular Basis of Lymphoid and Myeloid Diseases. **2009**, 265-290
- 32 Chromosomal Abnormalities in Selected Hematopoietic Malignancies Detected by Conventional and Molecular Cytogenetics: Diagnostic and Prognostic Significance. **2010**, 89-113
- 31 Basic Biostatistics for the Clinical Trialist. **2011**, 3-35

30	Novel Targeted Therapeutics for Acute Myeloid Leukemia. 2012 , 315-348		
29	Non-myeloablative allogeneic stem cell transplantation versus standard stem cell transplantation for haematological malignancies.		
28	Characterization and Use of an Antibody Detecting the CBFEBMMHC Fusion Protein in inv(16)/t(16;16)-Associated Acute Myeloid Leukemias. <i>Blood</i> , 1998 , 91, 1882-1890	2.2	
27	Acute Myeloid Leukemia. 2015 , 63-83		
26	Leukemia.		
25	Aging and Cancer. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2018 , 236-252	0.2	
24	VI. Chemotherapies for Leukemia in Elderly. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018 , 107, 1309-1315	0	
23	Acute Myeloid Leukemia in Older Adults. 2019 , 1-20		
22	Molecular Subtyping in Human Disease Using the Paraclique Algorithm. <i>Communications in Computer and Information Science</i> , 2019 , 54-58	0.3	
21	Advances in Acute Myeloid Leukemia Management: Focus on Secondary Disease and Older Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1785-1787	7.3	
20	Diagnosis and Classification of the Acute Myeloid Leukemias (with Discussion of the Role of the Myelodysplastic Syndromes in AML Pathogenesis). 2008 , 21-46		1
19	Insights into the Pathobiology of Secondary AML. <i>Hematologic Malignancies</i> , 2021 , 57-68	0	
18	Acetylshikonin induces autophagy-dependent apoptosis through the key LKB1-AMPK and PI3K/Akt-regulated mTOR signalling pathways in HL-60 cells.. <i>Journal of Cellular and Molecular Medicine</i> , 2022 ,	5.6	3
17	Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022 ,	2	
16	Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients.. <i>Blood</i> , 2022 ,	2.2	4
15	Whom should we treat with novel agents? Specific indications for specific and challenging populations. <i>Hematology American Society of Hematology Education Program</i> , 2021 , 2021, 24-29	3.1	
14	Management of acute myeloid leukemia. 26-42		
13	Aging and Cancer. 2022 , 1100-1116		

12	A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia.. <i>Investigational New Drugs</i> , 2022 , 1	4.3	
11	CPX-351 yields similar response and survival outcome in younger and older patients with secondary acute myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022 ,	2	0
10	Studying the potential of upregulated PTGS2 and VEGF-C besides hyper-methylation of PTGS2 promoter as biomarkers of Acute myeloid leukemia. <i>Molecular Biology Reports</i> ,	2.8	
9	How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> ,	5.4	1
8	Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. <i>Frontiers in Oncology</i> , 12,	5.3	0
7	A Novel Drug Modulator Diarylheptanoid (trans-1,7-Diphenyl-5-hydroxy-1-heptene) from Curcuma comosa Rhizomes for P-glycoprotein Function and Apoptosis Induction in K652/ADR Leukemic Cells. 2022 , 23, 8989		
6	Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia.		
5	Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. 2022 , 122, 106946		0
4	Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis. 2022 , 29, 7524-7536		0
3	Self-Assembled Daunorubicin/Epigallocatechin Gallate Nanocomplex for Synergistic Reversal of Chemoresistance in Leukemia. 2023 , 24, 381		0
2	Real-world experience with CPX-351 in high-risk acute myeloid leukemia. 2023 , 185, 103984		0
1	The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients. 2023 ,		0